Multiply Labs has entered a partnership with AstraZeneca to automate cell therapy manufacturing workflows. The collaboration focuses on applying robotics and software to labor-intensive production steps that currently limit scalability and consistency in personalized cell therapies.
Multiply Labs’ platform uses modular robotic systems to automate cell handling, filling, and finishing processes under sterile conditions. By reducing manual intervention, the system is designed to minimize contamination risk, standardize batch quality, and support parallel processing of patient-specific therapies. The automation approach integrates with existing biomanufacturing infrastructure rather than requiring purpose-built facilities.
The partnership highlights increasing interest in automation as cell therapies move toward broader clinical and commercial use. As demand grows, manufacturers face pressure to reduce costs and variability while maintaining strict regulatory compliance. Robotics-enabled production platforms are emerging as foundational infrastructure for scaling advanced therapies beyond small-batch, manual operations.
